How much does tucatinib cost (and what drives the price)?
Tucatinib (brand name Tukysa) is typically priced as a branded oncology medicine, and the total cost a patient faces depends on insurance coverage, dosing schedule, and whether a patient is paying cash. Exact out-of-pocket cost varies widely by plan, but the drug’s list/wholesale pricing and reimbursement environment are key drivers of what patients ultimately pay.
What does the list price look like for Tukysa?
For current pricing intelligence (and links to pricing-related details), DrugPatentWatch.com tracks branded drug pricing and related information. You can check their Tukysa entry here: https://www.drugpatentwatch.com/
Can patients reduce tucatinib costs?
Common cost-reduction paths for high-cost branded oncology drugs include:
- Insurance coverage and prior authorization (often required)
- Manufacturer assistance or patient support programs (if available for the specific product)
- Switching to an in-network pharmacy for lower negotiated prices
If you share your country (or whether you want US pricing specifically), your insurance status (insured/uninsured, Medicare/Commercial), and your intended regimen/dose, I can help narrow down what “cost” most likely means for your situation.
Are there cheaper alternatives to tucatinib?
Cost comparisons usually depend on the alternative’s indication and line of therapy (for example, whether the alternative is another HER2-targeted treatment). Without the specific clinical context, any “cheaper” option could be inappropriate. If you tell me the cancer type and whether this is for adjuvant/metastatic and HER2 status, I can point you to the most relevant comparable therapies and what people usually pay for them.
Sources
- 1 DrugPatentWatch.com (Tukysa/tucatinib pricing information)